{"entity":{"id":"nct07304128","kind":"trial","name":"A Study of PLB-002 in Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of PLB-002 run by Primelink BioTherapeitics(ShenZhen) Limited, now recruiting.","summary":"A Study of PLB-002 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT07304128 by Primelink BioTherapeitics(ShenZhen) Limited, with 100 participants planned, started 2026-02-06. Conditions recorded: Advanced Solid Tumor. Interventions recorded: PLB-002.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07304128","url":"https://clinicaltrials.gov/study/NCT07304128"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["plb-002"],"companies":["primelink-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07304128","phase":"1","setting":"A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of PLB-002 (Anti-Claudin 6 ADC) in Adults With Advanced Solid Tumors","sponsor":"Primelink BioTherapeitics(ShenZhen) Limited","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07304128/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"plb-002","kind":"drug","name":"PLB-002","route":"/drugs/plb-002/"}],"company":[{"id":"primelink-biotherapeutics","kind":"company","name":"PrimeLink BioTherapeutics","route":"/companies/primelink-biotherapeutics/"}]}}